Key Insights

Highlights

Treatment Research

1 treatments under study, led by Ervebo Vaccination

Research Leaders

6 sponsors active, led by Epicentre

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07903350Phase 4Recruiting

BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies

Showing all 1 trials

Research Network

Common Treatments

  • Ervebo Vaccination1

Active Sponsors

  • Epicentre1
  • Programme Elargi de Vaccination de République Démocratique du Congo1
  • Médecins Sans Frontières, France1
  • Institut National de Recherche Biomedicale (INRB)1
  • Institut national de santé publique, RDC1

Related Conditions

  • Ebola1

Activity Timeline